Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti‐HER2 targeted therapies

• Published in: Cancer Vol. 122; no. 17; pp. 2654 - 2662
• Main Authors: Ross, Jeffrey S., Gay, Laurie M., Wang, Kai, Ali, Siraj M., Chumsri, Saranya, Elvin, Julia A., Bose, Ron, Vergilio, Jo‐Anne, Suh, James, Yelensky, Roman, Lipson, Doron, Chmielecki, Juliann, Waintraub, Stanley, Leyland‐Jones, Brian, Miller, Vincent A., Stephens, Philip J.
• Format: Journal Article
• Language: English
• Published: United States 01.09.2016
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Biomarkers, Tumor - genetics; breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Carcinoma, Ductal, Breast - drug therapy; Carcinoma, Ductal, Breast - genetics; Carcinoma, Ductal, Breast - secondary; Carcinoma, Lobular - drug therapy; Carcinoma, Lobular - genetics; Carcinoma, Lobular - secondary; comprehensive genomic profiling; ERBB2; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic - drug effects; Genomics - methods; High-Throughput Nucleotide Sequencing - methods; human epidermal growth factor receptor 2 [HER2]/neu; Humans; In Situ Hybridization, Fluorescence; Lymphatic Metastasis; Middle Aged; Molecular Targeted Therapy; Mutation - genetics; Neoplasm Invasiveness; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - genetics; Neoplasm Recurrence, Local - pathology; Neoplasm Staging; next‐generation sequencing; Prognosis; Receptor, ErbB-2 - antagonists & inhibitors; Receptor, ErbB-2 - genetics; short variants; breast cancer; comprehensive genomic profiling; human epidermal growth factor receptor 2 [HER2]/neu; next-generation sequencing; short variants; ERBB2
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/cncr.30102

BACKGROUND Activating, nonamplification ERBB2 mutations (ERBB2mut) are not detected by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), but are detected by DNA sequencing and may predict clinical responses to human epidermal growth factor receptor (HER2)‐targeted therapy. The authors queried 5605 advanced/metastatic breast cancers (mBC) to uncover the frequency of ERBB2mut genomic alterations. Clinical responses to anti‐HER2 therapeutics were identified. METHODS DNA was extracted from 40 µm of formalin‐fixed paraffin‐embedded (FFPE) sections. Comprehensive genomic profiling (CGP) was used to evaluate up to 315 genes (592× mean coverage depth). Results were analyzed for base substitutions, short indels, copy number changes, and selected rearrangements. RESULTS Of 5605 cases, 698 (12.5%) featured ERBB2 alterations, including 596 (10.6%) ERBB2 amplifications (ERBB2amp) and 138 (2.4%) ERBB2mut; 38 cases (0.7%) had co‐occurring ERBB2amp and ERBB2mut. ERBB2mut predominantly affected the kinase (124 cases; 90%) or extracellular (15 cases; 11%) domains. Both primary BC (52 cases; 38%) and metastatic site biopsies (86 cases; 62%) were found to harbor ERBB2mut, which were distributed across carcinoma not otherwise specified (NOS) (69 cases; 50%), invasive ductal carcinoma (IDC) (40 cases; 29%), invasive lobular carcinoma (ILC) (27 cases; 20%), and mucinous mBC (2 cases; 1%). Genes commonly coaltered with ERBB2 were tumor protein 53 (TP53) (49%); phosphatidylinositol 3‐kinase catalytic subunit alpha (PIK3CA) (42%); cadherin 1, type 1 (CDH1) (37%); MYC (17%); and cyclin D1 protein (CCND1) (16%). CDH1 mutations were enriched in ERBB2mut mBC (P<0.0006) and associated with recurrent mBC. Selected patients with ERBB2mut, without ERBB2amp, who responded to anti‐HER2 targeted therapies are presented herein. CONCLUSIONS Within this large series, 1.8% of cases harbored ERBB2mut, which are undetectable by standard‐of‐care IHC or FISH tests. Metastatic BC driven by ERBB2mut respond to anti‐HER2 targeted therapies, and expanding clinical trials designed to detect ERBB2mut by CGP and optimize targeted treatments are warranted. Cancer 2016. © 2016 American Cancer Society. Cancer 2016;122:2654–2662. © 2016 American Cancer Society. Nonamplification ERBB2 mutations cannot be detected by standard‐of‐care immunohistochemistry or fluorescence in situ hybridization, although the presence of these alterations may predict response to human epidermal growth factor receptor 2‐targeted therapy. In a series of 5605 metastatic breast cancers, 2.4% of all cases and 20% of cases with ERBB2 alterations were found to harbor nonamplification mutations, which represents a substantial patient population who may benefit from human epidermal growth factor receptor 2‐targeted therapies.